Hepatitis

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

By

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

HCV Infection Linked to Nonhepatic Cancers in the Elderly

HCV Infection Linked to Nonhepatic Cancers in the Elderly

By

In the elderly population, hepatitis C virus infection is associated with cancers other than hepatocellular carcinoma, such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

Neuropsychiatric Impairment in Patients With HCV Despite Virus Clearance

By

Neuropsychiatric syndrome not linked to virus in hepatitis C infection.

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

Targeted CBT for HCV Patients Helps to Reduce Pain and Substance Use

By

Customized CBT reduced substance use disorder, pain severity, and pain interference in veterans with HCV.

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Short-Course Tocilizumab May Increase HBV Reactivation in RA

Three-dose tocilizumab combined with csDMARDs might increase the risk of HBV reactivation in RA patients with chronic HBV infection.

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

FDA Grants Priority Review to Fixed-Dose Pan-Genotypic HCV Regimen

By

Priority Review granted to the NDA of glecaprevir/pibrentasvir (G/P; AbbVie) for the treatment of genotypes 1-6 chronic hepatitis C virus infection.

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

Telemedicine Improves Hepatitis C Treatment Rates in Rural Areas

By

Using telemedicine consults with specialists to support PCPs enhanced the treatment rates in hepatitis C in rural areas.

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Reducing Diabetes Risk Key to Eradicating HCV in Coinfected Patients

Sustained viral response correlated with a significant decrease in the risk of diabetes mellitus and a trend towards decrease in chronic renal failure, according to a study.

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

Prophylactic Lamivudine Reduces HBV Flares During Chemotherapy

By

Patients with breast cancer who have chronic HBV infection have fewer flares while undergoing chemotherapy if they are treated with prophylactic lamivudine.

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

By

Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.

First HBV Quantitative Test to Assess Antiviral Therapy Response

First HBV Quantitative Test to Assess Antiviral Therapy Response

By

The new HBV test service from Quest Diagnostics measures the quantity of viral antigen to determine if the immune system is responding to treatment.

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Effectiveness of Sorafenib Dependent on Hepatitis Status in HCC

Meta-analysis shows consistent evidence that in advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival is dependent on patients' hepatitis status.

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Liver- and Non-Liver Related Critical Events Down in HCV and Cirrhosis

Researchers found that 50.5% of the patients achieved sustained viral response, which correlated with reduced incidence of hepatocellular carcinoma and hepatic decompensation.

HCV Antivirals Produce Durable Responses Despite Time to Suppression

HCV Antivirals Produce Durable Responses Despite Time to Suppression

By

Newer combinations of HCV genotype 1b antivirals showed sustained virologic response independent of time to viral suppression.

Higher Prevalence of Chronic HBV in Patients With Type 2 Diabetes

Higher Prevalence of Chronic HBV in Patients With Type 2 Diabetes

Researchers found that patients with type 2 diabetes had higher prevalence of chronic hepatitis B virus infection than the controls in the overall population.

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Ledipasvir-Sofosbuvir Effective in Treating Adolescents With HCV GT1

Phase 2 multi-center study examined the efficacy and safety of ledipasvir-sofosbuvir in 100 adolescents with chronic HCV genotype 1 infection.

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

Abbvie Submits New Drug Application to FDA for All Major HCV Genotypes

By

NDA submitted to the FDA by AbbVie for its investigational regimen of glecaprevir/pibrentasvir to treat all major genotypes of chronic HCV.

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes Increases Risk of Hepatocellular Carcinoma in HCV Patients

Diabetes increased the risk of hepatocellular carcinoma development and all-cause mortality in patients infected with HCV.

WHO Prequalifies First HCV Rapid Diagnostic Test

WHO Prequalifies First HCV Rapid Diagnostic Test

By

The World Health Organization has just prequalified its first hepatitis C virus point-of-care diagnostic test.

FDA: Review Underway for Single Tablet HCV Regimen

FDA: Review Underway for Single Tablet HCV Regimen

By

The once-daily single tablet regimen of sofosbuvir/velpatasvir/voxilaprevir is intended for patients with direct-acting antiviral-experienced hepatitis C infections.

Elevated Risk of HBV Reactivation in Patients With RA

Elevated Risk of HBV Reactivation in Patients With RA

By

In patients with rheumatoid arthritis, low baseline hepatitis B surface antibody titers are significant risk factors for HBV reactivation.

HOMA2-IR May Assess Risk of Hepatocellular Carcinoma in Chronic HBV

HOMA2-IR May Assess Risk of Hepatocellular Carcinoma in Chronic HBV

Homeostasis Model Assessment Index (HOMA2-IR) may be used to stratify the risk of hepatocellular carcinoma in chronic HBV.

After Improper Dental Care, VA Offers Hepatitis, HIV Screening to Veterans

After Improper Dental Care, VA Offers Hepatitis, HIV Screening to Veterans

By

Tomah VA Medical Center in Wisconsin advises veterans to get screened for hepatitis and HIV after receiving improper dental care.

Impact of Maternal HBsAg Carrier Status on Neonatal Outcomes

Impact of Maternal HBsAg Carrier Status on Neonatal Outcomes

By

Infants born to mothers who test positive for HBsAg are at higher risk for congenital malformations.

Ledipasvir-sofosbuvir Ok'd for Kidney Recipients With HCV

Ledipasvir-sofosbuvir Ok'd for Kidney Recipients With HCV

Safety and efficacy was shown in kidney transplant recipients with hepatitis C virus genotype 1 or 4 infection.

HCV Treatment Before Liver Transplant Increases Life Expectancy

HCV Treatment Before Liver Transplant Increases Life Expectancy

HCV treatment before liver transplant increased life expectancy if model for end-stage liver disease was ≤ 27.

Low Incidence of Late Recurrent Viremia With Ledipasvir/Sofosbuvir

Low Incidence of Late Recurrent Viremia With Ledipasvir/Sofosbuvir

By

Researchers evaluated the prevalence of late recurrent viremia following sofosbuvir-based treatment.

Possible Interaction Between HCV Treatment Identified

Possible Interaction Between HCV Treatment Identified

Probable interaction between paritaprevir/ritonavir/ombitasvir+dasabuvir (PrOD) plus ribavirin with warfarin identified in a case report.

WHO: New Hepatitis C Drugs Reaches More Than 1 Million People

WHO: New Hepatitis C Drugs Reaches More Than 1 Million People

High prices have been a barrier to HCV treatment but WHO reports that prices in low- and certain middle-income countries are declining.

ID Specialist Involvement Key to Successfully Treating Hepatitis C

ID Specialist Involvement Key to Successfully Treating Hepatitis C

By

ID specialists need to take a major role in the implementation of new treatments for HCV.

Sign Up for Free e-newsletters